NEW YORK, Dec. 15, 2017 — Law360 has named Atlanta-based King & Spalding partner Andrew Bayman a 2017 Product Liability MVP. Bayman earned this recognition for, among other achievements, helping significantly mitigate GlaxoSmithKline’s damages in a closely watched federal trial over a generic version of the drug Paxil®, which was the first lawsuit ever tried under a theory of “innovator liability.” Click here to read Law360’s full profile (subscription required).
The Law360 MVPs list recognizes lawyers “who have distinguished themselves from their peers over the past year through high-stakes litigation, record-breaking deals and complex global matters.”
Bayman co-chairs King & Spalding’s Life Sciences and Healthcare practice, and represents clients in every segment of the life sciences industry. He is also member of King & Spalding’s policy committee, and has served in many other firm leadership positions.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,000 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.